Evidence mapPaperPMID 33112845Full record

ArticlePLoS medicine2020

Defining remission of type 2 diabetes in research studies: A systematic scoping review.

Mireille Captieux, Regina Prigge, Sarah Wild, Bruce Guthrie

Abstract readScoping Review
In one paragraph

Article in PLoS medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Type 2 Diabetes Mellitus Remission, Dream or Reality? A Narrative Review of Current Evidence and Integrated Care Strategies.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025
    Review
  7. Article
  8. Article
  9. Remission of type 2 diabetes: A critical appraisal.Frontiers in endocrinology · 2023
    Article
  10. Article
  11. Article
  12. Article
  13. Remission of type 2 diabetes after gastrectomy for gastric cancer: diabetes prediction score.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2022
    Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mireille CaptieuxUsher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, United Kingdom.ORCID 0000-0002-4367-9274
Regina PriggeUsher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, United Kingdom.ORCID 0000-0002-0489-684X
Sarah WildUsher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, United Kingdom.ORCID 0000-0001-7824-2569
Bruce GuthrieUsher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, United Kingdom.ORCID 0000-0003-4191-4880

Funding

Chief Scientist Office CAF 18/12Chief Scientist Office CAF/18/12
6 · The paper itself

Abstract

backgroundRemission has been identified as a top priority by people with type 2 diabetes. Remission is commonly used as an outcome in research studies; however, a widely accepted definition of remission of type 2 diabetes is lacking. A report on defining remission was published (but not formally endorsed) in Diabetes Care, an American Diabetes Association (ADA) journal. This Diabetes Care report remains widely used. It was the first to suggest 3 components necessary to define the presence of remission: (1) absence of glucose-lowering therapy (GLT); (2) normoglycaemia; and (3) for duration ≥1 year. Our aim is to systematically review how remission of type 2 diabetes has been defined by observational and interventional studies since publication of the 2009 report. METHODS AND

findingsFour databases (MEDLINE, EMBASE, Cochrane Library, and CINAHL) were searched for studies published from 1 September 2009 to 18 July 2020 involving at least 100 participants with type 2 diabetes in their remission analysis, which examined an outcome of type 2 diabetes remission in adults ≥18 years and which had been published in English since 2009. Remission definitions were extracted and categorised by glucose-lowering therapy, glycaemic thresholds, and duration. A total of 8,966 titles/abstracts were screened, and 178 studies (165 observational and 13 interventional) from 33 countries were included. These contributed 266 definitions, of which 96 were unique. The 2009 report was referenced in 121 (45%) definitions. In total, 247 (93%) definitions required the absence of GLT, and 232 (87%) definitions specified numeric glycaemic thresholds. The most frequently used threshold was HbA1c<42 mmol/mol (6.0%) in 47 (20%) definitions. Time was frequently omitted. In this study, a total of 104 (39%) definitions defined time as a duration. The main limitations of this systematic review lie in the restriction to published studies written in English with sample sizes of over 100. Grey literature was not included in the search.

conclusionsWe found that there is substantial heterogeneity in the definition of type 2 diabetes remission in research studies published since 2009, at least partly reflecting ambiguity in the 2009 report. This complicates interpretation of previous research on remission of type 2 diabetes and the implications for people with type 2 diabetes. Any new consensus definition of remission should include unambiguous glycaemic thresholds and emphasise duration. Until an international consensus is reached, studies describing remission should clearly define all 3 components of remission. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42019144619.

Indexed as

AdultBlood GlucoseDiabetes Mellitus, Type 2FemaleGlucoseHumansMaleRemission InductionRemission, SpontaneousBlood GlucoseGlucose

Identifiers

PMID33112845
PMCPMC7592769

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.